# US 2008/0305099 A1 · Pharmaceutical Composition, Composition for Screening Therapeutics Preventing and Treating Beta Amyloid Accumulation in Brain Comprising Gcp II (Glutamate Carboxypeptidase II) as an Active Ingredient and Method for Screening Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305099 A1
- Document ID: US20080305099A1
- Status: Published application
- Kind: A1
- Application number: 12/064,426
- Filed: 2006-08-23
- Published: 2008-12-11
- Earliest claimed: 2005-08-23
- Assignees: Korea Center for Disease Control and Prevention
- Inventors: Sang-Mee Ahn; So Young Seo; San Sook Chae
- Web page: https://patentgrep.com/patent/US20080305099A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for the prevention and treatment for β-amyloid(Aβ) accumulation in brain comprising GCP-II (Glutamate carboxypeptidase-II) as an active ingredient, a composition for screening method of the same. GCP-II of the present invention not only degrades Aβ monomer and oligomer but also degrades soluble Aβ and insoluble Aβ, particularly aggregated Aβ, so that it can prevent the accumulation of Aβ in brain or reduce the accumulation, making it an excellent candidate for the therapeutic agent for Alzheimer's disease and Down's syndrome.

## Claims

### Claim 1

A pharmaceutical composition for the prevention and treatment of Aβ accumulation in brain containing GCP-II protein as an active ingredient.

### Claim 2 (depends on 1)

The pharmaceutical composition for the prevention and treatment of Aβ accumulation in brain according to claim 1, wherein the GCP-II protein has an amino acid sequence represented by SEQ. ID. NO: 2.

### Claim 3 (depends on 2)

The pharmaceutical composition for the prevention and treatment of Aβ accumulation in brain according to claim 2, wherein a gene encoding the GCP-II has a nucleotide sequence represented by SEQ. ID. NO: 1.

### Claim 4 (depends on 1)

The pharmaceutical composition for the prevention and treatment of Aβ accumulation in brain according to claim 1, wherein the Aβ is soluble or insoluble Aβ.

### Claim 5

A composition for screening a preventive and therapeutic agent for inhibiting Aβ accumulation in brain comprising a human GCP-II gene.

### Claim 6 (depends on 5)

The composition for screening a preventive and therapeutic agent for inhibiting Aβ accumulation in brain according to claim 5, wherein the human GCP-II gene includes one or more nucleotide sequences selected from a group consisting of a nucleotide sequence represented by SEQ. ID. NO: 1, a nucleotide sequence containing a polymorphism of the sequence represented by SEQ. ID. NO: 1 or a nucleotide sequence of a gene fragment containing the polymorphism.

### Claim 7

A composition for screening a preventive and therapeutic agent for inhibiting Aβ accumulation in brain containing human GCP-II protein.

### Claim 8 (depends on 7)

The composition for screening a preventive and therapeutic agent for inhibiting Aβ accumulation in brain according to claim 7, wherein the human GCP-II protein includes one or more proteins selected from a group consisting of a protein having an amino acid sequence represented by SEQ. ID. NO: 2, a protein expressed from the nucleotide sequence represented by SEQ. ID. NO: 1 or from the nucleotide sequence containing the polymorphism of SEQ. ID. NO: 1 and GCP-II polypeptide fragments exhibiting similar physiological activity to GCP-11.

### Claim 9 (depends on 5)

A screening method for identifying a preventive and therapeutic agent for inhibiting Aβ accumulation in brain comprising the following steps:
i) contacting the composition of claim 5 to a test subject; and
ii) determining whether the composition increases or inhibits the expression of the gene by observing the reaction of step i).

### Claim 10 (depends on 7)

A screening method for identifying a preventive and therapeutic agent for inhibiting Aβ accumulation in brain comprising the following steps:
i) contacting the composition of claim 7 to a test subject; and
ii) determining whether the composition increases or inhibits the expression of the protein by observing the reaction of step i).

### Claim 11

A preventive and therapeutic agent for inhibiting Aβ accumulation in brain, wherein the agent comprises a GCP-II expression vector as an active ingredient.

### Claim 12 (depends on 11)

The preventive and therapeutic agent for inhibiting Aβ accumulation in brain according to claim 11, wherein the expression vector is one or more viral expression vectors selected from a group consisting of adenovirus, adeno-associated virus, lenti-virus, retrovirus and vaccinia virus expression vectors.

### Claim 13

A method for prevention and treatment for Aβ accumulation in brain of a subject comprising the following step:
administering a therapeutically effective dose of a recombinant expression vector encoding a GCP-II protein to a test subject.

### Claim 14 (depends on 13)

A method for a prevention and treatment for Aβ accumulation in brain according to claim 13, wherein the GCP-II protein has an amino acid sequence represented by SEQ. ID. NO: 2.

### Claim 15 (depends on 13)

A method for a prevention and treatment for Aβ accumulation in brain according to claim 13, wherein the GCP-II protein has an amino acid sequence represented by SEQ. ID. NO: 1.

### Claim 16 (depends on 13)

A method for a prevention and treatment for Aβaccumulation in brain according to claim 13, wherein the therapeutically effective dose is 0.1 μg/kg-0.1 g/kg.
